Business Details
Bexion Pharmaceuticals: Targeted Cancer Therapies
Bexion Pharmaceuticals was founded with a mission to transform cancer care through innovative biologics. Our lead compound, BXQ-350, represents a groundbreaking approach to treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). By modulating sphingolipid metabolism, we target both cancer progression and its associated neuropathic pain, addressing critical unmet medical needs. Our team of seasoned professionals brings decades of oncology and biopharma expertise, having previously led major drug developments at institutions like Genentech, Merck, and Pfizer. We have advanced BXQ-350 through Phase 1b/2 trials with promising data in metastatic colorectal cancer and completed a proof-of-concept study for CIPN.Backed by over 30 years of preclinical research, our science leverages Saposin C to activate sphingolipids, creating an anti-tumor environment while protecting nerve cells. We collaborate closely with patient advocacy groups and maintain strict FDA compliance, prioritizing patient safety and quality of life. Our Covington, KY headquarters houses a dedicated R&D team working to expand BXQ-350's applications into broader oncology and neuropathy indications. With strong institutional support and a clear focus on clinical-stage innovation, we aim to redefine treatment paradigms for difficult-to-treat cancers.
Services
Cancer Therapy Development
Clinical Trial Management
Biologic Research
Neuropathy Treatment
Pharmacokinetic Studies
Translational Research
Oncology Drug Development
Patient Advocacy Collaboration
Regulatory Affairs
Preclinical Testing
Highlights and features
- Our team has 200+ combined years of oncology drug development experience at major pharmaceutical firms
- BXQ-350 is the only known therapy modulating sphingolipid metabolism for dual cancer/neuropathy effects
- Completed Phase 1b/2 trial in metastatic colorectal cancer with encouraging efficacy signals
- Established safety profile with only 1 SAE across 1100+ doses administered
- Scientific founders with 30+ years of sphingolipid research expertise
Services
Cancer Therapy Development
Developing targeted biologics for advanced cancers, focusing on metastatic colorectal cancer. BXQ-350 modulates sphingolipid metabolism to induce tumor cell death while enhancing patient outcomes. Our approach combines over 30 years of preclinical research with recent clinical validation.
Neuropathy Management
Addressing chemotherapy-induced peripheral neuropathy through sphingolipid pathway modulation. BXQ-350 demonstrates neuroprotective properties in clinical trials, potentially reducing dose-limiting toxicities and improving treatment adherence for cancer patients.
Clinical Trial Management
Conducting Phase 1b/2 trials for BXQ-350 in metastatic colorectal cancer and pediatric brain tumors. Our program follows FDA guidelines, with completed enrollment in open-label trials showing promising efficacy signals and safety profiles.
Biologic Research
Investigating sphingolipid metabolism mechanisms using proprietary technology. Our research demonstrates how Saposin C activates enzymes to increase tumor-suppressing ceramides while reducing cancer-promoting S1P levels.
Patient Advocacy Collaboration
Partnering with oncology patient organizations to align research priorities with patient needs. We work to ensure our therapies address real-world challenges faced by cancer patients and caregivers during treatment.
People
Jim Beach
Chief Executive Officer
20+ years leading healthcare organizations including Cardinal Health, Johnson & Johnson, and GE Healthcare. Chemical Engineering graduate from Queens University with Six Sigma certification.
Tariq Arshad
Chief Medical Officer
Board-certified oncologist with 20+ years in pharmaceutical industry. Led blockbuster drug launches at Genentech, Merck, and Pfizer. Recipient of Pharmaceutical Executive's 45 Under 45 leadership award.
Ray Takigiku
Founder
30+ years pharmaceutical R&D experience. Founder of Bexion and former P&G Pharmaceuticals executive. Served as CEO until 2022, instrumental in developing BXQ-350's foundational technology.
Gilles Tapolsky
VP, Pharmacology
30+ years in drug development with major contributions to oncology therapies. Holds 60+ patents. Former CSO at Advanced Cancer Therapeutics with expertise in preclinical and clinical research.
Charles R. Scheper
Chairman of the Board
Former COO of Great American Financial Resources. Cancer survivor actively involved with Cancer Support Community. Currently leads local economic development initiatives in Northern Kentucky.
Questions
What makes BXQ-350 unique compared to other cancer treatments?
BXQ-350 uniquely modulates sphingolipid metabolism to simultaneously target tumor cells and address chemotherapy-induced neuropathy through its dual mechanism of action.
Which cancers are currently being studied in Bexion's clinical trials?
Phase 1b/2 trials are evaluating BXQ-350 in metastatic colorectal cancer and pediatric brain tumors, with preclinical exploration of additional solid tumors.
How does BXQ-350 address chemotherapy side effects?
BXQ-350 shows potential to reduce chemotherapy-induced peripheral neuropathy by modulating sphingolipid pathways involved in both cancer and nerve cell health.
What clinical trial phases has BXQ-350 completed?
BXQ-350 has completed Phase 1 trials across 20+ tumor types, an open-label Phase 1b/2 trial in metastatic colorectal cancer, and a proof-of-concept study for CIPN.
